Spero Therapeutics, Inc.

SPRO
NASDAQ
Last Updated: 9/28/2022 12:25:33 PM
Price
2.02
Changes
-0.07
% Change
-3.35
Volume
9903445
52 Week
High
19.14
52 Week
Low
0.68
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics, Inc. Company Details
CEO:   Dr. Ankit Mahadevia
Country:   US
Industry:   Biotechnology
Website:   https://sperotherapeutics.com
Exchange:   NASDAQ Global Select
IPO\Launch Date:   2017-11-02
Spero Therapeutics, Inc. Company Executive Details
  Mr. Timothy Keutzer
  Chief Devel. Officer
  Mr. James P. Brady
  Chief Human Resource Officer
  Mr. David Musselman
  Senior Vice President of Sales & Market Access
  Ms. Tamara Lynn Joseph L.L.M., J.D.
  Chief Legal Officer
  Ted Jenkins
  Vice President & Head of Investor Relations

Spero Therapeutics, Inc. Latest News

Hot Penny Stocks To Watch As The Stock Market Crash Continues


Hot penny stocks to add to your watch list this week. Is it time to buy?


Published on: 2022-09-26 14:30:16

Impact on Symbol / Company: SPRO

View News

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK


The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.


Published on: 2022-09-23 12:47:39

Impact on Symbol / Company: SPRO

View News

Reddit Penny Stocks to Watch as September Ends


Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.


Published on: 2022-09-23 06:00:00

Impact on Symbol / Company: SPRO

View News

Spero's stock jumps 188% after GSK licenses experimental antibiotic


Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.


Published on: 2022-09-22 10:53:42

Impact on Symbol / Company: SPRO

View News

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement


Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics.


Published on: 2022-09-22 09:56:02

Impact on Symbol / Company: SPRO

View News

Looking for Popular Penny Stocks to Buy? 3 to Watch Now


Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?


Published on: 2022-09-08 06:00:00

Impact on Symbol / Company: SPRO

View News

Spero (SPRO) Up Following Positive FDA Update for UTI Drug


Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.


Published on: 2022-09-07 12:02:17

Impact on Symbol / Company: SPRO

View News

Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?


Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).


Published on: 2022-09-07 10:34:10

Impact on Symbol / Company: SPRO

View News

Spero Therapeutics to Present at Upcoming Investor Conference


CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022. Details for the presentation are as follows:


Published on: 2022-09-07 08:05:00

Impact on Symbol / Company: SPRO

View News

Are These Penny Stocks on Your September Buy List?


Here's what you need to know about buying penny stocks on September 7th The post Are These Penny Stocks on Your September Buy List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.


Published on: 2022-09-07 06:00:00

Impact on Symbol / Company: SPRO

View News

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call Transcript


Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Ted Jenkins - Vice President-Investor Relations & Strategic Finance Ankit Mahadevia - Chief Executive Officer David Melnick - Consultant & Senior Clinical Advisor Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics Second Quarter 2022 Financial Results Conference Call.


Published on: 2022-08-11 19:09:18

Impact on Symbol / Company: SPRO

View News

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates


Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?


Published on: 2022-08-10 18:48:23

Impact on Symbol / Company: SPRO

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you